Although it saw sales fall last year, AbbVie Inc.’s Japanese subsidiary says it intends “to continue double-digit growth through 2025,” with hematologic oncology and immunology the main therapeutic focus areas.
The operation logged sales of JPY113.7bn ($1.04bn) in calendar 2020, a decrease of 9% from the previous year, hit in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?